What P&G just reported (fiscal Q2 FY26; quarter ended December 2025)
- Net sales: $22.2B, +1% YoY; organic sales flat as roughly +1% pricing offset about –1% volume.
- EPS: GAAP $1.78 (–5%) on higher restructuring; core EPS $1.88 (flat).
- Cash & returns: $5.0B operating cash flow; 88% adjusted free cash flow productivity; $4.8B returned to shareholders (≈$2.5B dividends, ≈$2.3B buybacks).
Where the growth (and drag) came from
- Beauty: +4% organic, premiumization and pricing doing the heavy lifting.
- Grooming: flat organic; price held, volumes lighter.
- Health Care: +3% organic, strength in premium oral care and OTC.
- Fabric & Home Care: flat organic; Home Care up low single digits.
- Baby, Feminine & Family: –4% organic, with Family Care down double-digits on tough comps.
Regions: 5 of 7 grew organically, led by Latin America (+8%) and Europe Enterprise (+6%); the U.S. was the pressure point on softer category trends and a tough base.
Margin and cost backdrop
Core gross margin fell 50 bps (reported gross margin –120 bps). Pricing (+50 bps) and productivity savings (+160 bps)were more than offset by unfavorable mix (–120 bps), reinvestment (–60 bps) and tariffs (–60 bps). Core operating margin was –70 bps year over year.
Outlook: guidance intact where it matters
- Sales: FY26 all-in +1% to +5%; organic in-line to +4%.
- Earnings: Core EPS growth flat to +4% (=$6.83–$7.09; midpoint $6.96). GAAP EPS growth +1% to +6%given restructuring.
- Macro levers: FX a modest tailwind (≈$200M after tax); tariffs ≈$400M after tax headwind; commodities roughly neutral; tax rate ~20–21%. Cash returns still aimed at ~$10B dividends and ~$5B buybacks in FY26.
Read on the tape: what this quarter says about the stock
The good: The core algorithm is intact. Pricing power held up, premium trade-ups continued in Beauty and Health, and P&G kept funding brand/media and product superiority while grinding out productivity. Cash conversion was strong, and guidance for organic growth and core EPS stayed unchanged—implying a second-half acceleration as reinvestment and innovation cycles hit shelves.
The watch-outs: Volumes haven’t broadly re-accelerated; mix was a notable drag; and Family Care’s come-down from last year’s surge weighed on totals. Tariffs remain a real headwind even with some FX relief, and the GAAP EPS guide-down reflects restructuring flowing through this year.
Investment preview: base case, bull case, bear case
Base case (next 6–12 months):
Expect low-single-digit organic growth with modest volume improvement as innovation resets in Fabric/Home and BBF cycle through. Core EPS up ~0–4% on productivity and a neutral commodities backdrop. Multiple likely stays supported by consistent cash returns and staples defensiveness.
Bull case:
Volumes inflect across big baskets (detergent, diapers) as elasticities normalize, premium trade-ups resume, and Europe/LatAm strength persists. Tariff impact proves milder, enabling margin re-expansion toward the top half of the core EPS guide—supporting multiple resilience.
Bear case:
U.S. category softness lingers (especially tissue/towel), promo intensity rises, and tariff frictions persist—keeping mix negative and margins capped. The H2 acceleration underwhelms, forcing heavier reinvestment and leaving EPS at the bottom end of guidance.
Key catalysts to watch
- H2 launch slate and shelf resets in Fabric & Home and BBF;
- Margin cadence vs. tariff/FX math;
- U.S. tissue/towel category trends and promo intensity;
- Restructuring cost curve and timing of benefits;
- Cash return cadence relative to the buyback plan.
Bottom line for Procter
This was a “hold the line” quarter: revenue a touch soft, but core EPS steady, cash strong, and guidance intact where it matters. If management delivers the second-half pickup—and tariffs don’t worsen—the setup favors defensive compounding over dramatic upside. For long-term holders, the thesis remains pricing power + productivity + brand investment; near term, watch for a volume/mix turn and stabilization in Family Care.
FAQ
What surprised the market most?
The flat organic sales versus hopes for a small positive, and the GAAP EPS guide trim tied to restructuring—even as core EPS guidance stayed unchanged.
Is P&G still buying back stock and paying dividends?
Yes. FY26 plans call for roughly $10B in dividends and $5B in repurchases, with $4.8B already returned in the quarter.
Where did P&G grow?
By segment: Beauty and Health Care led; Fabric & Home was stable; Baby/Feminine/Family declined. By region: Latin America and Europe Enterprise stood out.
What could improve results in H2?
Innovation resets in big categories, normalizing U.S. category demand, and a neutral commodities backdrop—provided tariffs don’t escalate.
Disclaimer
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Financial markets involve risk, including the possible loss of principal. Always conduct your own research or consult a licensed financial adviser before making investment decisions. Figures and guidance referenced reflect management commentary for the period ended December 2025 and may change subsequently.
